Want to see ORMP full AI Analyst Report?
Oramed Pharm (ORMP) Ratios
Oramed Pharm Ratios
ORMP's free cash flow for Q2 2026 was $-202.00K. For the 2026 fiscal year, ORMP's free cash flow was decreased by $-2.00K and operating cash flow was $-200.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Sep 23 | Dec 22 | Aug 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 |
| Quick Ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 |
| Cash Ratio | 2.41 | 9.57 | 0.17 | 7.04 | 11.57 |
| Solvency Ratio | 2.06 | -1.90 | 0.10 | -3.26 | -1.93 |
| Operating Cash Flow Ratio | -0.48 | -1.48 | -0.19 | -4.99 | -3.17 |
| Short-Term Operating Cash Flow Coverage | -32.09 | 0.00 | -0.20 | -116.20 | -162.93 |
| Net Current Asset Value | $ 102.15M | $ 133.29M | $ 104.93M | $ 146.62M | $ 83.86M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.23 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.32 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.24 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.16 | 1.06 | 1.35 | 1.06 | 1.11 |
| Debt Service Coverage Ratio | 225.04 | -21.17 | 0.13 | -150.11 | -162.95 |
| Interest Coverage Ratio | 0.00 | -14.98 | -4.40 | 0.00 | -4037.17 |
| Debt to Market Cap | 0.00 | 0.00 | 0.55 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.03 | 1.37 | 0.02 | 0.02 |
| Net Debt to EBITDA | -0.60 | 3.63 | 5.81 | 1.07 | 3.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.65% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 3766.20% | 0.00% | 531.72% | -1501.96% | 0.00% |
| EBITDA Margin | 3772.25% | 0.00% | 546.34% | -1367.96% | -926.34% |
| Operating Profit Margin | -754.40% | 0.00% | -1176.79% | -1501.96% | -896.15% |
| Pretax Profit Margin | 3766.20% | 0.00% | 379.70% | -1393.41% | -850.50% |
| Net Profit Margin | 3202.50% | 0.00% | 412.31% | -1397.11% | -822.72% |
| Continuous Operations Profit Margin | 3200.80% | 0.00% | 379.70% | -1397.11% | 0.00% |
| Net Income Per EBT | 85.03% | 119.99% | 108.59% | 100.27% | 96.73% |
| EBT Per EBIT | -499.23% | 124.56% | -32.27% | 92.77% | 94.91% |
| Return on Assets (ROA) | 27.74% | -12.30% | 2.51% | -23.36% | -17.37% |
| Return on Equity (ROE) | 32.07% | -13.06% | 3.37% | -24.88% | -19.21% |
| Return on Capital Employed (ROCE) | -7.12% | -8.54% | -9.42% | -26.04% | -19.97% |
| Return on Invested Capital (ROIC) | -6.05% | -8.53% | -7.21% | -26.00% | -17.45% |
| Return on Tangible Assets | 27.74% | -12.30% | 2.51% | -23.36% | -17.37% |
| Earnings Yield | 54.28% | -19.33% | 5.93% | -8.05% | -3.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 4.49 | 0.24 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.50 | 0.00 | 0.86 | 1.49 | 2.90 |
| Asset Turnover | 0.01 | 0.00 | 0.01 | 0.02 | 0.02 |
| Working Capital Turnover Ratio | 0.02 | 0.00 | 0.01 | 0.02 | 0.04 |
| Cash Conversion Cycle | 764.69 | -1492.15 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 846.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 81.38 | 1492.15 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 846.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.22 | -0.21 | -0.26 | -0.74 | -0.74 |
| Free Cash Flow Per Share | -0.27 | -0.21 | -0.26 | -0.75 | -0.76 |
| Dividend Paid and CapEx Coverage Ratio | -4.73 | -467.36 | -40.53 | -57.87 | -56.48 |
| Capital Expenditure Coverage Ratio | -4.73 | -467.36 | -40.53 | -57.87 | -56.48 |
| Operating Cash Flow Coverage Ratio | -11.08 | -22.61 | -0.20 | -32.10 | -39.74 |
| Operating Cash Flow to Sales Ratio | -4.57 | 0.00 | -7.68 | -10.62 | -7.84 |
| Free Cash Flow Yield | -9.39% | -8.53% | -11.33% | -6.22% | -3.85% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 1.86 | -5.15 | 16.86 | -12.42 | -25.19 |
| Price-to-Sales (P/S) Ratio | 59.00 | 0.00 | 69.50 | 173.56 | 207.28 |
| Price-to-Book (P/B) Ratio | 0.59 | 0.68 | 0.57 | 3.09 | 4.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.65 | -11.72 | -8.83 | -16.07 | -25.99 |
| Price-to-Operating Cash Flow Ratio | -12.90 | -11.75 | -9.05 | -16.35 | -26.45 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.01 | -0.15 | -0.51 | -0.64 |
| Enterprise Value Multiple | 0.97 | -3.01 | 18.54 | -11.62 | -19.31 |
| Enterprise Value | 72.88M | 44.76M | 135.69M | 429.57M | 483.56M |
| EV to EBITDA | 0.97 | -3.01 | 18.54 | -11.62 | -19.31 |
| EV to Sales | 36.44 | 0.00 | 101.26 | 158.92 | 178.90 |
| EV to Free Cash Flow | -6.58 | -5.31 | -12.86 | -14.71 | -22.43 |
| EV to Operating Cash Flow | -7.97 | -5.32 | -13.18 | -14.97 | -22.83 |
| Tangible Book Value Per Share | 4.82 | 3.56 | 4.04 | 3.88 | 4.09 |
| Shareholders’ Equity Per Share | 4.82 | 3.58 | 4.06 | 3.89 | 4.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | -0.20 | 0.00 | -0.00 | 0.13 |
| Revenue Per Share | 0.05 | 0.00 | 0.03 | 0.07 | 0.09 |
| Net Income Per Share | 1.55 | -0.47 | 0.14 | -0.97 | -0.78 |
| Tax Burden | 0.85 | 1.20 | 1.09 | 1.00 | 0.97 |
| Interest Burden | 1.00 | 1.06 | 0.71 | 0.93 | 0.00 |
| Research & Development to Revenue | 3.19 | 0.00 | 6.69 | 10.23 | 7.77 |
| SG&A to Revenue | 4.36 | 0.00 | 6.29 | 5.11 | 2.20 |
| Stock-Based Compensation to Revenue | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.14 | 0.44 | -1.86 | 0.79 | 0.95 |
Currency in USD
